Clinical Trials in Philadelphia

Showing 6781-6800 of 20,904 trials

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT04626583

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

Mesenchymal Stromal CellsCorneaSafety+1 more

University of Illinois at Chicago8 participantsStarted Mar 2021

Chicago, Illinois, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 1< 1 mile

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176

The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.

Gastrointestinal Stromal TumorsGISTNon-resectable Advanced Solid Tumors+1 more

Blueprint Medicines Corporation10 participantsStarted Aug 2022

Jacksonville, Florida, United States • Ann Arbor, Michigan, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202

The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.

Schizophrenia

Vanda Pharmaceuticals593 participantsStarted Nov 2005

Little Rock, Arkansas, United States • Anaheim, California, United States • Cerritos, California, United States +39 more locations

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells

A Drug-drug Interaction Study of Avapritinib and Midazolam

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Find Trials by Condition in Philadelphia

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

AAV Gene Therapy Study for Subjects with PKU

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

An Age-Stratified Data Collection Study to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II

Study of ATH434 in Participants with Multiple System Atrophy

Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Biomarkers to Predict Time to Plasma HIV RNA Rebound

Risk of Recurrent CeAD After Pregnancy